Please try another search
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company has a collaboration with Evotec SE. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Name | Age | Since | Title |
---|---|---|---|
Peer Michael Schatz | 57 | 2020 | Independent Chairman of the Supervisory Board |
Guido Alexander Prehn | 45 | 2017 | Independent Member of the Supervisory Board |
Hubert Birner | 57 | 2017 | Independent Member of the Supervisory Board |
Jonathan G. Sheldon | 51 | 2020 | Independent Member of the Supervisory Board |
Eric Souêtre | 67 | 2017 | Independent Member of the Supervisory Board |
Mary Blake Sheahan | 51 | 2022 | Member of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review